Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.

King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L; STAART Psychopharmacology Network.

Arch Gen Psychiatry. 2009 Jun;66(6):583-90. doi: 10.1001/archgenpsychiatry.2009.30.

2.

Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.

King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, Hollander E, Bregman JD, Anagnostou E, Robinson F, Sullivan L, Hirtz D.

JAMA Pediatr. 2013 Nov;167(11):1045-52. doi: 10.1001/jamapediatrics.2013.2698.

3.

Use of citalopram in pervasive developmental disorders.

Namerow L, Thomas P, Bostic JQ, Prince J, Monuteaux MC.

J Dev Behav Pediatr. 2003 Apr;24(2):104-8.

PMID:
12692455
4.

Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior.

Volkmar FR.

Arch Gen Psychiatry. 2009 Jun;66(6):581-2. doi: 10.1001/archgenpsychiatry.2009.42. No abstract available.

PMID:
19487622
5.

Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism.

Mouti A, Reddihough D, Marraffa C, Hazell P, Wray J, Lee K, Kohn M.

Trials. 2014 Jun 16;15:230. doi: 10.1186/1745-6215-15-230.

6.

A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders.

Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C.

Am J Psychiatry. 2012 Mar;169(3):292-9. doi: 10.1176/appi.ajp.2011.10050764. Erratum in: Am J Psychiatry. 2012 May;169(5):540.

PMID:
22193531
7.

Drug fails to subdue repetitive behavior in children with autism spectrum disorders.

[No authors listed]

Harv Ment Health Lett. 2009 Oct;26(4):7. No abstract available.

PMID:
19904836
8.

Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.

Storch EA, Wilhelm S, Sprich S, Henin A, Micco J, Small BJ, McGuire J, Mutch PJ, Lewin AB, Murphy TK, Geller DA.

JAMA Psychiatry. 2016 Aug 1;73(8):779-88. doi: 10.1001/jamapsychiatry.2016.1128.

PMID:
27367832
9.

Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.

March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee FR, Wagner KD, Steiner H.

JAMA. 1998 Nov 25;280(20):1752-6. Erratum in: JAMA 2000 Mar 8;283(10):1293.

PMID:
9842950
10.

Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.

Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):599-610.

PMID:
17069548
11.
12.

An open trial of divalproex sodium in autism spectrum disorders.

Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S.

J Clin Psychiatry. 2001 Jul;62(7):530-4.

PMID:
11488363
13.

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).

Williams K, Brignell A, Randall M, Silove N, Hazell P.

Cochrane Database Syst Rev. 2013 Aug 20;(8):CD004677. doi: 10.1002/14651858.CD004677.pub3. Review.

PMID:
23959778
14.

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.

Feighner JP, Overø K.

J Clin Psychiatry. 1999 Dec;60(12):824-30.

PMID:
10665628
15.

Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders.

Scahill L, McCracken JT, Bearss K, Robinson F, Hollander E, King B, Bregman J, Sikich L, Dukes K, Sullivan L, Anagnostou E, Donnelly C, Kim YS, Ritz L, Hirtz D, Wagner A.

J Autism Dev Disord. 2012 Mar;42(3):432-40. doi: 10.1007/s10803-011-1251-8.

PMID:
21667200
16.

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.

Research Units on Pediatric Psychopharmacology Autism Network.

Arch Gen Psychiatry. 2005 Nov;62(11):1266-74.

PMID:
16275814
17.

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.

Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):541-8.

PMID:
17069543
18.

Pharmacological treatment options for autism spectrum disorders in children and adolescents.

Leskovec TJ, Rowles BM, Findling RL.

Harv Rev Psychiatry. 2008;16(2):97-112. doi: 10.1080/10673220802075852. Review.

PMID:
18415882
19.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
20.

Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.

McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B.

Am J Psychiatry. 2005 Jun;162(6):1142-8.

PMID:
15930063

Supplemental Content

Support Center